Future Therapeutics in Psoriasis

  • Abigail Cline
  • Kayla H. Felix
  • Elias Oussedik
  • Leah A. CardwellEmail author
  • Steven R. Feldman
Part of the Updates in Clinical Dermatology book series (UCD)


In recent years, investigations into psoriasis pathophysiology have expanded the development of immunomodulatory and biological molecules. These advancements have transformed treatment regimens for psoriasis by selectively targeting immune signaling molecules. The aim of this chapter is to review the clinical and research data surrounding these emerging treatments, ranging from those undergoing development to those already in clinical trials. Therapies are organized by method of administration (topicals, orals, and injectables) and then phase of clinical trial. Many of these promising medications are small-molecule inhibitors and biologics, while some draw from traditional mechanisms of actions like steroids and vitamin analogs. It is too soon to know how effective these future agents will be and where they will fit into treatment algorithms. It will remain critical for clinicians to be aware of the limitations, important monitoring, and drug safety when selecting these novel treatments. However, even as the psoriasis treatment armamentarium continues to expand, many psoriasis patients may continue to experience recalcitrant disease.


Psoriasis Treatment regimens Emerging treatments Immunomodulatory molecules Biological molecules 


  1. 1.
    Nestle FO, Kaplan DH, Barker J Psoriasis. N Engl J Med [Internet]. 2009 [cited 2017 May 8];361:496–509.
  2. 2.
    Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol [Internet]. 2008 [cited 2017 May 8];58:826–50.
  3. 3.
    Jensen AM, Lladó MB, Skov L, Hansen ER, Larsen JK, Baadsgaard O. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol [Internet]. 1998 [cited 2017 Apr 27];139:984–91.
  4. 4.
    Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol [Internet]. 1992 [cited 2017 Apr 27];27:1001–8.
  5. 5.
    Dimitris R, Palmieri R, Caserini M, Iorizzo M. Phase-2 controlled study to assess the efficacy of two new nail solutions in the treatment of nail psoriasis. J Am Acad Dermatol [Internet]. Elsevier; 2016 [cited 2017 Apr 28];74:AB137.
  6. 6.
    Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol [Internet]. 2001 [cited 2017 Apr 27];2:95–120.
  7. 7.
    Georgiou S, Tsambaos D. Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol. Acta Derm Venereol [Internet]. 1999 [cited 2017 Apr 25];79:86.
  8. 8.
    Valeant Pharmaceuticals Announces Results of Second Phase 3 Study for Psoriasis Treatment IDP-118 – Valeant [Internet]. [cited 2017 Apr 28].
  9. 9.
    Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients—Full Text View— [Internet]. [cited 2017 May 8].
  10. 10.
    Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis—Full Text View— [Internet]. [cited 2017 May 8].
  11. 11.
    Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients—Full Text View— [Internet]. [cited 2017 May 8].
  12. 12.
    Boguniewicz M, Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Call RS, et al. Efficacy and safety of crisaborole topical ointment, 2%, a novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase inhibitor in 2 Phase 3 studies in children and adults with mild-to-moderate atopic dermatitis. J Allergy Clin Immunol [Internet]. 2016 [cited 2017 Apr 28];137:AB397.
  13. 13.
    AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis—Study Results— [Internet]. [cited 2017 May 10].
  14. 14.
    Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol [Internet]. 2016 [cited 2017 Apr 28];75:494–503.e6.
  15. 15.
    Roblin D, Yosipovitch G, Boyce B, Robinson J, Sandy J, Mainero V, et al. Topical TrkA Kinase Inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a Phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol [Internet]. 2015 [cited 2017 Apr 27];95:542–8.
  16. 16.
    Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol [Internet]. 2012 [cited 2017 Apr 28];2012:1–16.
  17. 17.
    Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol [Internet]. Springer International Publishing; 2000 [cited 2017 Apr 26];1:245–50.
  18. 18.
    A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis—Full Text View— [Internet]. [cited 2017 May 8].
  19. 19.
    An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis—Full Text View— [Internet]. [cited 2017 May 8].
  20. 20.
    PH-10 For Psoriasis [Internet]. [cited 2017 Apr 28].
  21. 21.
    Randomized Study of PH-10 for Psoriasis—Full Text View— [Internet]. [cited 2017 May 8].
  22. 22.
    Bissonnette R, Bolduc C, Maari C, Nigen S, Webster JM, Tang L, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol [Internet]. Blackwell Publishing Ltd; 2011 [cited 2017 Apr 26];26.
  23. 23.
    Zhao L, Chen X, Cai L, Zhang C, Wang Q, Jing S, et al. Randomized, double-blind, placebo-controlled, multiple-dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis. J Clin Pharm Ther [Internet]. 2014 [cited 2017 Apr 26];39:418–23.
  24. 24.
    Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol [Internet]. 2013 [cited 2017 Apr 27];169:137–45.
  25. 25.
    Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol [Internet]. 2016 [cited 2017 Apr 27];16:15.
  26. 26.
  27. 27.
    Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers—Full Text View— [Internet]. [cited 2017 May 8].
  28. 28.
    XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis|Business Wire [Internet]. [cited 2017 May 8].
  29. 29.
    Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci [Internet]. 2014 [cited 2017 Apr 29];111:16814–9.
  30. 30.
    Zanin-Zhorov A, Weiss JM, Trzeciak A, Chen W, Zhang J, Nyuydzefe MS, et al. Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10. J Immunol [Internet]. 2017 [cited 2017 Apr 29].
  31. 31.
    NCI Thesaurus-Alitretinoin [Internet]. [cited 2017 Apr 29].
  32. 32.
    Irla N, Navarini AA, Yawalkar N. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol [Internet]. Blackwell Publishing Ltd; 2012 [cited 2017 Apr 29];167:1170–4.
  33. 33.
    Reich K, Graff O, Mehta N. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study. Br J Dermatol [Internet]. 2016 [cited 2017 Apr 29];174:1277–81.
  34. 34.
    NCI Thesaurus-Baricitinib [Internet]. [cited 2017 Apr 29].
  35. 35.
    Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol [Internet]. 2016 [cited 2017 Apr 29];174:1266–76.
  36. 36.
    Nawas Z, Hatch M, Ramos E, Liu M, Tong Y, Peranteau A, et al. A review of guselkumab, an IL-23 inhibitor, for moderate-to-severe plaque psoriasis. Skin Ther Lett [Internet]. 2017 [cited 2017 Apr 28];22:8–10.
  37. 37.
    Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol [Internet]. 2014 [cited 2017 Apr 28];133:1032–40.
  38. 38.
    Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A Phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med [Internet]. Massachusetts Medical Society; 2015 [cited 2017 Apr 28];373:136–44.
  39. 39.
    Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen Y-K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol [Internet]. 2017 [cited 2017 Apr 28];76:405–17.
  40. 40.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol [Internet]. 2017 [cited 2017 Apr 28];76:418–31.
  41. 41.
    Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature [Internet]. 2015 [cited 2017 Apr 28];521:222–6.
  42. 42.
    Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol [Internet]. 2015 [cited 2017 Apr 28];173:930–9.
  43. 43.
    Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol [Internet]. 2015 [cited 2017 Apr 29];136:116–124.e7.
  44. 44.
    Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour J-P, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N. Engl. J. Med. [Internet]. Massachusetts Medical Society; 2017 [cited 2017 Apr 29];376:1551–60.
  45. 45.
    Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. [Internet]. Wiley Subscription Services, Inc., A Wiley Company; 2011 [cited 2017 Apr 29];63:939–48.
  46. 46.
    Silverman D, Oliver A. Abatacept-induced psoriasis. Cutis [Internet]. 2011 [cited 2017 Apr 29];88:117–8.
  47. 47.
    Brigant F, Clavel G, Chatelain D, Lok C, Chaby G. Letter: a case of generalized guttate psoriasis induced by etanercept with relapse after abatacept. Dermatol Online J [Internet]. 2011 [cited 2017 Apr 29];17:11.
  48. 48.
    Florent A, Albert C, Giacchero D, Roux C, Euller-Ziegler L. Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Joint Bone Spine [Internet]. 2010 [cited 2017 Apr 29];77:626–7.
  49. 49.
    Jost C, Hermann J, Caelen LE-S, Graninger W. New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis. BMJ Case Rep [Internet]. 2009 [cited 2017 Apr 29];2009:bcr0920080845.
  50. 50.
    Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol [Internet]. [cited 2017 Apr 29];25:S46–56.
  51. 51.
    Lubrano E, Perrotta FM. Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis. Drugs [Internet]. Springer International Publishing; 2016 [cited 2017 Apr 28];76:663–73.
  52. 52.
  53. 53.
    A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis—Full Text View— [Internet]. [cited 2017 May 8].
  54. 54.
    Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, et al. The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a Phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol [Internet]. 2016 [cited 2017 Apr 28];68:2163–73.
  55. 55.
    Abufarag A, Aigner S, Czeloth N, Dalken B, Koch H, Niemann G, Uherek C, Osterroth F, Wartenberg-Demand A, Haefeli W, Schopf R, Enk A. Selective activation of naturally occurring regulatory T cells (Tregs) by the monoclonal antibody BT-061 as a novel therapeutic opportunity in psoriasis: early clinical results after single doses [Internet]. [cited 2017 Apr 29].
  56. 56.
    Huizinga TWJ, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, et al. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther [Internet]. 2017 [cited 2017 Apr 29];19:53.
  57. 57.
    NCI Thesaurus-Namilumab [Internet]. [cited 2017 Apr 29].
  58. 58.
    Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis—Study Results— [Internet]. [cited 2017 May 8].
  59. 59.
    Hari A, Flach TL, Shi Y, Mydlarski PR. Toll-like receptors: role in dermatological disease. Mediators Inflamm [Internet]. Hindawi Publishing Corporation; 2010 [cited 2017 Apr 29];2010:437246.
  60. 60.
    Balak DMW, Van Doorn A, Rissmann R, Sullivan T, Burggraaf J, Arbeit RD. Results from a randomized, double-blind, placebo-controlled, monotherapy trial of IMO-8400 demonstrate clinical proof- of-concept for Toll-like receptor 7, 8 and 9 antagonism in psoriasis. [cited 2017 Apr 29];

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Abigail Cline
    • 1
  • Kayla H. Felix
    • 2
  • Elias Oussedik
    • 2
  • Leah A. Cardwell
    • 2
    Email author
  • Steven R. Feldman
    • 2
    • 3
    • 4
  1. 1.Department of Internal MedicineMedical College of GeorgiaAugustaUSA
  2. 2.Department of DermatologyWake Forest School of MedicineWinston-SalemUSA
  3. 3.Department of PathologyWake Forest School of MedicineWinston-SalemUSA
  4. 4.Department of Public Health SciencesWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations